一分钟看懂
这是一项关于食管鳞状细胞癌的II 期研究,登记的药物或干预包括Toripalimab (240mg day1, Q3W*3cycle),当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Toripalimab (240mg day1, Q3W*3cycle) · II 期
登记条件中文摘要
年龄范围:18岁至75岁
登记的基本范围为不限性别,年龄18岁至75岁;以下仅摘录3项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出2项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- Nanfang Hospital, Southern Medical University · 广州
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- * 1: age 18-75 years old, both sexes; 2: esophageal squamous cell carcinoma confirmed by histopathology; 3: T2-4a, N0-3, M0 (AJCC 8th edition) thoracic esophageal cancer patients, resectable by surgical evaluation; 4: initial treatment patients without anti-tumor therapy; 5: expected survival time ≥6 months; 6: ECOG ≤1; 7: There was no history of esophageal perforation, active esophageal bleeding, and no obvious invasion of trachea or thoracic large vessels.
- 8: The function of vital organs meets the following requirements: white blood cell ≥4.0×109/l, neutrophil ≥1.5×109/l, platelet ≥100.0×109/l, hemoglobin ≥90g/l; Serum albumin ≥2.8g/Dl; Total bilirubin ≤1.5 × ULN, ALT/AST/ AKP≤2.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance \> 60 mL/min; There were no severe organic diseases.
- 9: FEV1 ≥ 0.8L; 10: Patients were informed about the trial details and signed informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT06843889;登记信息更新于 2025-04-16;本站同步于 2026-11-21。